Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is well-positioned for above-average growth with their increased focus on technology-driven supply-chain solutions and diversified client base. Their partnership with Symbotic and launch of the AI-driven Mpower platform further strengthens their competitive advantage in the market. The company's strong performance in the U.S. market, successful implementation of major health system solutions, and plans for organic growth support a positive outlook for Medline's stock as it continues to expand globally with its advanced technology and diverse product offerings.

Bears say

Medline is poised for strong growth and margin expansion through its prime vendor flywheel, AI-driven operating efficiencies, and potential for M&A and geographical expansion. Additionally, the company has high retention rates and a vertically integrated manufacturing process that allows for control over costs and quality, leading to attractive margins for their Medline-branded products. Medline's MPower platform and partnerships with AI and robotics companies also position the company for long-term success in the healthcare supply chain industry.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.